Greenwich LifeSciences, Inc. (GLSI) Balance Sheet
GLSI balance sheet, 2025
December 31, 2025 · U.S. dollars$6.2M assets = $5.8M liabilities + $353,217 equity
Both columns are drawn to the same scale: what GLSI owns equals what it owes plus shareholders’ equity. Hover a block for its value.
GLSI financial health
Descriptive bands, not a rating. Fiscal 2025.
GLSI balance sheet trends, 2017–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $27,1042017 | $6.2M2025 | +97.1%/yr | |
| Total liabilities | $8.6M2017 | $5.8M2025 | −4.7%/yr | |
| Shareholders’ equity | −$8.5M2017 | $353,2172025 | — | |
| Cash & short-term investments | $542017 | $6.2M2025 | +328.9%/yr | |
| Total debt | $420,1542018 | $275,1542020 | −19.1%/yr | |
| Net cash (debt) | −$335,0522018 | $28.4M2020 | +$28.7M | |
| Working capital | −$557,4492017 | $353,2172025 | +$910,666 | |
| Book value per share | −$0.732017 | $0.032025 | — | |
| Current ratio | 0.002017 | 1.062025 | +1.06 | |
| Shares outstanding | 11.7M2017 | 13.5M2025 | +1.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GLSI assets
GLSI liabilities and equity
GLSI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
GLSI balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M | $6,835 | $85,102 | $54 |
| Cash & equivalents | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M | $6,835 | $85,102 | $54 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total current assets | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M | $6,835 | $85,102 | $54 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $1,779 | $5,391 | $9,003 | $12,615 | $16,227 | $19,836 | $23,443 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $27,050 |
| Total assets | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M | $26,671 | $108,545 | $27,104 |
| Liabilities | |||||||||
| Accounts payable | $4.9M | $2.8M | $35,472 | $220,845 | $220,845 | $710,971 | $730,309 | $277,556 | $161,146 |
| Short-term debt | — | — | — | — | — | $275,154 | $635,154 | — | — |
| Deferred revenue | — | — | — | — | — | −$275 | −$635 | −$420,154 | — |
| Total current liabilities | $5.8M | $3.2M | $294,406 | $262,905 | $385,172 | $1.0M | $1.4M | $728,599 | $557,503 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $730,309 | $9.5M | $8.0M |
| Total liabilities | $5.8M | $3.2M | $294,406 | $262,905 | $385,172 | $1.0M | $1.4M | $10.2M | $8.6M |
| Shareholders' equity | |||||||||
| Common stock & paid-in capital | $14,299 | $13,153 | $12,848 | $12,848 | $13,148 | $12,704 | $8,458 | $542 | $542 |
| Retained earnings (deficit) | −$87.1M | −$67.8M | −$50.4M | −$41.5M | −$33.6M | −$29.1M | −$27.2M | −$23.8M | −$22.1M |
| Accumulated other comprehensive income | — | — | $0 | — | $0 | $0 | — | — | −$541 |
| Total shareholders' equity | $353,217 | $908,626 | $6.7M | $13.2M | $26.8M | $27.6M | −$1.4M | −$10.1M | −$8.5M |
| Key figures | |||||||||
| Total debt | — | — | — | — | — | $275,154 | $635,154 | $420,154 | — |
| Net cash (debt) | — | — | — | — | — | $28.4M | −$628,319 | −$335,052 | — |
| Working capital | $353,217 | $906,847 | $6.7M | $13.2M | $26.8M | $27.6M | −$1.4M | −$643,497 | −$557,449 |
| Tangible book value | $353,217 | $906,847 | $6.7M | $13.2M | $26.8M | $27.6M | −$1.4M | −$10.1M | −$8.5M |
| Book value per share | $0.03 | $0.07 | $0.52 | $1.02 | $2.07 | $2.18 | −$0.11 | −$0.85 | −$0.73 |
| Shares outstanding | 13.5M | 13.0M | 12.8M | 12.9M | 12.9M | 12.7M | 11.7M | 12.0M | 11.7M |
| Current ratio | 1.06 | 1.28 | 23.74 | 51.23 | 70.63 | 27.41 | 0.00 | 0.12 | 0.00 |
| Quick ratio | 1.06 | 1.28 | 23.74 | 51.23 | 70.63 | 27.41 | 0.00 | 0.12 | 0.00 |
| Debt / equity | — | — | — | — | — | 0.01 | — | — | — |
| Equity / assets | 5.7% | 22.2% | 95.8% | 98.0% | 98.6% | 96.4% | −5,063.2% | −9,323.4% | −31,472.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $8.9M | $10.5M | $6.2M | $3.8M | $3.1M | $2.7M | $4.1M | $5.8M | $7.2M | $5.5M | $7.0M | $9.1M |
| Cash & equivalents | $8.9M | $10.5M | $6.2M | $3.8M | $3.1M | $2.7M | $4.1M | $5.8M | $7.2M | $5.5M | $7.0M | $9.1M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2,682 | $0 | $0 | $0 | $0 |
| Total current assets | $8.9M | $10.5M | $6.2M | $3.8M | $3.1M | $2.7M | $4.1M | $5.8M | $7.2M | $5.5M | $7.0M | $9.1M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $876 | $1,779 | $2,682 | $3,585 | $4,488 | $5,391 | $6,294 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $8.9M | $10.5M | $6.2M | $3.8M | $3.1M | $2.8M | $4.1M | $5.8M | $7.2M | $5.5M | $7.0M | $9.1M |
| Liabilities | ||||||||||||
| Accounts payable | $4.8M | $4.5M | $4.9M | $1.1M | $1.1M | $827,036 | $1.2M | $774,759 | $1.1M | $125,737 | $256,317 | $10,057 |
| Total current liabilities | $5.8M | $5.2M | $5.8M | $1.6M | $1.7M | $1.4M | $1.6M | $842,384 | $1.4M | $389,611 | $294,406 | $297,287 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $5.8M | $5.2M | $5.8M | $1.6M | $1.7M | $1.4M | $1.6M | $842,384 | $1.4M | $389,611 | $294,406 | $297,287 |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $14,678 | $14,666 | — | $13,795 | $13,473 | $13,193 | — | $13,145 | $13,068 | $12,876 | — | $12,848 |
| Retained earnings (deficit) | −$96.7M | −$92.8M | −$87.1M | −$77.6M | −$73.4M | −$69.4M | −$66.2M | −$58.1M | −$55.4M | −$52.8M | −$50.4M | −$47.6M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | — | $0 | — | — |
| Total shareholders' equity | $3.1M | $5.3M | $353,217 | $2.2M | $1.4M | $1.3M | $2.5M | $5.0M | $5.9M | $5.1M | $6.7M | $8.9M |
| Key figures | ||||||||||||
| Working capital | $3.1M | $5.3M | $353,217 | $2.2M | $1.4M | $1.3M | $2.5M | $5.0M | $5.9M | $5.1M | $6.7M | $8.8M |
| Tangible book value | $3.1M | $5.3M | $353,217 | $2.2M | $1.4M | $1.3M | $2.5M | $5.0M | $5.9M | $5.1M | $6.7M | $8.8M |
| Book value per share | $0.21 | $0.36 | $0.02 | $0.16 | $0.11 | $0.10 | $0.19 | $0.38 | $0.46 | $0.40 | $0.52 | $0.69 |
| Shares outstanding | 14.6M | 14.6M | 14.3M | 13.6M | 13.4M | 13.2M | 13.2M | 13.1M | 12.9M | 12.9M | 12.8M | 12.8M |
| Current ratio | 1.54 | 2.01 | 1.06 | 2.35 | 1.85 | 1.91 | 2.62 | 6.91 | 5.34 | 14.13 | 23.74 | 30.76 |
| Quick ratio | 1.54 | 2.01 | 1.06 | 2.35 | 1.85 | 1.91 | 2.62 | 6.91 | 5.34 | 14.13 | 23.74 | 30.76 |
| Equity / assets | 35.1% | 50.2% | 5.7% | 57.4% | 46.1% | 47.7% | 61.9% | 85.5% | 81.3% | 92.9% | 95.8% | 96.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed June 1, 2026); data from EODHD.
GLSI financial position
At the end of fiscal 2025 (December 31, 2025), Greenwich LifeSciences had total assets of $6.2 million (up 50.9% from a year earlier), total liabilities of $5.8 million and shareholders' equity of $0.4 million. Its current ratio was 1.06. In the latest quarter (ended June 30, 2026) total assets were $8.9 million and equity $3.1 million.
Related: GLSI income statement, GLSI cash flow statement, GLSI key metrics. See the GLSI stock overview for the latest quote and news.
GLSI balance sheet FAQ
What are Greenwich LifeSciences's total assets?
Greenwich LifeSciences reported total assets of $6.2 million at the end of fiscal 2025 (December 31, 2025), compared with $4.1 million a year earlier.
How much cash does Greenwich LifeSciences have?
Greenwich LifeSciences held $6.2 million in cash and short-term investments at the end of fiscal 2025.
What is Greenwich LifeSciences's book value?
Greenwich LifeSciences's shareholders' equity (book value) was $0.4 million at the end of fiscal 2025, or $0.03 per share.
What is Greenwich LifeSciences's current ratio?
Greenwich LifeSciences had current assets of $6.2 million and current liabilities of $5.8 million, a current ratio of 1.06 (it can cover its short-term obligations).